FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/New Study Evaluates Peptide Therapies for Liver Disease Prevention
研究ライブラリに戻る

New Study Evaluates Peptide Therapies for Liver Disease Prevention

May 25, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

New Study Evaluates Peptide Therapies for Liver Disease Prevention

A groundbreaking Phase 3 study has been launched to assess whether the peptide therapies tirzepatide and retatrutide can prevent major adverse liver outcomes (MALO) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). This research, titled SYNERGY-Outcomes, is sponsored by Eli Lilly and Company and aims to provide valuable insights into the potential benefits of these peptide treatments.

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD), also known as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), is a growing health concern affecting millions around the world. The condition is characterized by an accumulation of fat in the liver and can lead to inflammation, fibrosis, cirrhosis, and even liver cancer if left untreated.

Peptide therapies like tirzepatide and retatrutide have shown promise in managing metabolic disorders such as type 2 diabetes and obesity. These peptides work by targeting specific receptors in the body to regulate metabolism and appetite control. The SYNERGY-Outcomes study seeks to determine whether these peptides can also protect against severe liver complications associated with MASLD.

Key Details

The SYNERGY-Outcomes trial is currently recruiting adults who are at high risk of developing major adverse liver outcomes due to metabolic dysfunction-associated steatotic liver disease (MASLD). Participants will be randomly assigned within a Master Protocol to receive either retatrutide, tirzepatide, or a placebo. The primary goal is to assess whether these peptide therapies can prevent serious liver complications in patients with MASLD.

The study, which is being conducted across multiple sites and sponsored by Eli Lilly and Company, will employ non-invasive tests (NITs) to identify eligible participants who are at high risk of developing MALO. This approach allows for a more precise identification of individuals most likely to benefit from the intervention.

Key Takeaways

  • Assessing Peptide Efficacy: The SYNERGY-Outcomes study aims to evaluate whether tirzepatide and retatrutide can prevent major adverse liver outcomes in patients with MASLD.
  • Non-Invasive Testing: Eligibility for the trial is determined using non-invasive tests, ensuring that participants are at high risk of developing serious liver complications.
  • Master Protocol Design: The study employs a Master Protocol design to efficiently test multiple agents within a single clinical trial framework.
  • Long-Term Impact: Results from this research could significantly impact future treatment guidelines and peptide therapy options for managing MASLD.

What This Means

For the peptide community, the SYNERGY-Outcomes study represents an important step forward in understanding the potential of peptide therapies beyond metabolic disorders. If successful, these findings may lead to new FDA-approved treatments that can protect against severe liver conditions associated with MASLD. Such advancements would not only improve patient outcomes but also further establish peptide therapy as a versatile and effective treatment modality.

---

Source: ClinicalTrials.gov — Published 2026-05-22

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。